Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein-Barr Virus Reactivation

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2020 Jan 8

PMID 31908501

Citations 5

Authors

Krzysztof Czyzewski

Magdalena Dziedzic

Malgorzata Salamonowicz

Jowita Fraczkiewicz

Olga Zajac-Spychala

Agnieszka Zaucha-Prazmo

Jolanta Gozdzik

Przemyslaw Galazka

Natalia Bartoszewicz

Ewa Demidowicz

Jan Styczynski

Affiliations

Soon will be listed here.

Abstract

Objective: The analysis of epidemiology, risk factors and outcome of viral infections in children and adolescents after hematopoietic cell transplantation (HCT).

Methods: In this multicenter nationwide study a total of 971 HCT procedures (741 allo-HCT; 230 auto-HCT) over a period of 6 years were analyzed.

Results: During this period 801 episodes of viral infections were diagnosed in 442 patients. The incidence of viral infections was 57.9% in allo-HCT and 4.8% in auto-HCT patients. The most frequent infections after allo-HCT were caused by cytomegalovirus (CMV), polyoma BK virus (BKV) and Epstein-Barr virus (EBV). The majority of infections occurred within the first 4 months after allo-HCT and over 80% required pharmacotherapy or symptomatic therapy. The median time of treatment of specific viral infection ranged from 7 (for EBV) to 24 (for CMV) days. The highest mortality was observed in case of CMV infection. The risk factors for viral infections were allo-HCT, acute leukemia, acute and chronic graft versus host disease (a/cGVHD), and matched unrelated donor (MUD)/mismatched unrelated donor (MMUD)-HCT. The risk factor for death from viral infection were CMV-IgG seropositivity in acute lymphoblastic leukemia recipient, and MUD/MMUD-HCT. The incidence of EBV infection requiring pre-emptive treatment with rituximab in allo-HCT children was 19.3%. In 30.8% cases of EBV infection, these episodes were preceded by other viral infection and treated with antivirals, which did not prevent development of EBV-DNA-emia with need of rituximab treatment in 81.5% cases. In 47.7% of these cases, GVHD was a factor enabling development of significant EBV-DNA-emia during antiviral therapy of other infection.

Conclusion: We have shown that antiviral drugs do not prevent EBV reactivation in allo-HCT pediatric patients.

Citing Articles

Fully Human Herpesvirus-Specific Neutralizing IgG Antibodies Generated by EBV Immortalization of Splenocytes-Derived from Immunized Humanized Mice.

Theobald S, Fiestas E, Schneider A, Ostermann B, Danisch S, von Kaisenberg C Cells. 2024; 13(1).

PMID: 38201224 PMC: 10778511. DOI: 10.3390/cells13010020.

Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients.

Maximova N, Nistico D, Luci G, Simeone R, Piscianz E, Segat L Front Pharmacol. 2022; 13:865871.

PMID: 35496277 PMC: 9050193. DOI: 10.3389/fphar.2022.865871.

Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Sobkowiak-Sobierajska A, Lindemans C, Sykora T, Wachowiak J, Dalle J, Bonig H Front Pediatr. 2022; 10:808103.

PMID: 35252060 PMC: 8894895. DOI: 10.3389/fped.2022.808103.

Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation.

Cheng A, Cheng M, Loy C, Lenz J, Chen K, Smalling S Proc Natl Acad Sci U S A. 2022; 119(4).

PMID: 35058359 PMC: 8795552. DOI: 10.1073/pnas.2113476118.

Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein-Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant.

Diop N, Bonong P, Buteau C, Duval M, Lacroix J, Laporte L Vaccines (Basel). 2021; 9(6).

PMID: 34200239 PMC: 8226807. DOI: 10.3390/vaccines9060610.

References

Marr K . Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology Am Soc Hematol Educ Program. 2012; 2012:265-70. PMC: 4696052. DOI: 10.1182/asheducation-2012.1.265. View

Styczynski J, Gil L . Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplant. 2008; 42 Suppl 2:S77-81. DOI: 10.1038/bmt.2008.289. View

Srinivasan A, McLaughlin L, Wang C, Srivastava D, Shook D, Leung W . Early infections after autologous hematopoietic stem cell transplantation in children and adolescents: the St. Jude experience. Transpl Infect Dis. 2013; 16(1):90-7. PMC: 4003497. DOI: 10.1111/tid.12165. View

Srinivasan A, Wang C, Srivastava D, Burnette K, Shenep J, Leung W . Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 19(1):94-101. PMC: 3554248. DOI: 10.1016/j.bbmt.2012.08.012. View

Hirsch H, Martino R, Ward K, Boeckh M, Einsele H, Ljungman P . Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2012; 56(2):258-66. PMC: 3526251. DOI: 10.1093/cid/cis844. View

van Kraaij M, Dekker A, Verdonck L, van Loon A, Vinje J, Koopmans M . Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant. 2000; 26(3):299-303. PMC: 7091909. DOI: 10.1038/sj.bmt.1702484. View

Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill J . Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(8):e260-e272. DOI: 10.1016/S1473-3099(19)30107-0. View

Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S . Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the.... J Clin Oncol. 2016; 34(19):2212-20. DOI: 10.1200/JCO.2015.64.2405. View

Matthes-Martin S, Feuchtinger T, Shaw P, Engelhard D, Hirsch H, Cordonnier C . European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012; 14(6):555-63. DOI: 10.1111/tid.12022. View

10.

Hiwarkar P, Gaspar H, Gilmour K, Jagani M, Chiesa R, Bennett-Rees N . Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant. 2012; 48(6):803-8. DOI: 10.1038/bmt.2012.221. View

11.

Styczynski J, Czyzewski K, Wysocki M, Gryniewicz-Kwiatkowska O, Kolodziejczyk-Gietka A, Salamonowicz M . Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect. 2015; 22(2):179.e1-179.e10. DOI: 10.1016/j.cmi.2015.10.017. View

12.

Czyzewski K, Galazka P, Zalas-Wiecek P, Gryniewicz-Kwiatkowska O, Gietka A, Semczuk K . Infectious complications in children with malignant bone tumors: a multicenter nationwide study. Infect Drug Resist. 2019; 12:1471-1480. PMC: 6549759. DOI: 10.2147/IDR.S199657. View

13.

Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward K . Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2008; 43(10):757-70. DOI: 10.1038/bmt.2008.386. View

14.

Cesaro S, Dalianis T, Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H . ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2017; 73(1):12-21. DOI: 10.1093/jac/dkx324. View

15.

Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P . European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis. 2013; 15(3):219-32. DOI: 10.1111/tid.12054. View

16.

Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P . Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008; 42(4):227-40. DOI: 10.1038/bmt.2008.162. View

17.

Lin R, Liu Q . Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2013; 6:94. PMC: 3878524. DOI: 10.1186/1756-8722-6-94. View

18.

Mikulska M, Del Bono V, Gandolfo N, Dini S, Dominietto A, di Grazia C . Epidemiology of viral respiratory tract infections in an outpatient haematology facility. Ann Hematol. 2013; 93(4):669-76. PMC: 7079995. DOI: 10.1007/s00277-013-1912-0. View

19.

Styczynski J . Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation. Infect Dis Ther. 2017; 7(1):1-16. PMC: 5840099. DOI: 10.1007/s40121-017-0180-z. View

20.

Styczynski J, Einsele H, Gil L, Ljungman P . Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009; 11(5):383-92. DOI: 10.1111/j.1399-3062.2009.00411.x. View